Results 11 to 20 of about 8,468,954 (280)

The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data [PDF]

Pharmacogenomics and Personalized Medicine
Nina L Wittwer,1,2 Christoph R Meier,1– 3 Carola A Huber,4 Julie D Moser,1 Henriette E Meyer zu Schwabedissen,5 Samuel S Allemann,6,* Cornelia Schneider1,2,* 1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,
Wittwer NL, Meier CR, Huber CA, Moser JD, Meyer zu Schwabedissen HE, Allemann SS, Schneider C   +6 more
doaj   +4 more sources

Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative. [PDF]

J Pers Med, 2020
We explored the association between CYP2C19/3A4 mediated drug-gene-interaction (DGI), drug-drug-interaction (DDI) and drug-drug-gene-interaction (DDGI) and (es)citalopram dispensing course.
Bahar MA, Lanting P, Bos JHJ, Sijmons RH, Hak E, Wilffert B.   +5 more
europepmc   +6 more sources

Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug-drug-gene interaction network. [PDF]

CPT Pharmacometrics Syst Pharmacol, 2023
Abstract The antiarrhythmic agent quinidine is a potent inhibitor of cytochrome P450 (CYP) 2D6 and P‐glycoprotein (P‐gp) and is therefore recommended for use in clinical drug–drug interaction (DDI) studies. However, as quinidine is also a substrate of CYP3A4 and P‐gp, it is susceptible to DDIs involving these proteins. Physiologically‐
Feick D, Rüdesheim S, Marok FZ, Selzer D, Loer HLH, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T.   +11 more
europepmc   +5 more sources

A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development. [PDF]

Clin Pharmacol Ther
Conducting clinical studies on drug–drug‐gene interactions (DDGIs) and extrapolating the findings into clinical dose recommendations is challenging due to the high complexity of these interactions. Here, physiologically‐based pharmacokinetic (PBPK) modeling networks present a new avenue for exploring such complex scenarios, potentially informing ...
Rüdesheim S, Loer HLH, Feick D, Marok FZ, Fuhr LM, Selzer D, Teutonico D, Schneider ARP, Solodenko J, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T.   +14 more
europepmc   +5 more sources

Drug‐Drug‐Gene Interactions: A Call for Clinical Consideration [PDF]

Clinical Pharmacology & Therapeutics, 2021
It is widely accepted that both comedications and genetic factors may contribute to variation of drug response. Clinical decision support systems increasingly consider recommendations on drug– drug interactions (DDIs) during electronic prescribing, and some guidelines on drug–gene-interactions (DGI) have been implemented in drug labels.
Bruckmüller, Henrike, Cascorbi, Ingolf
openaire   +3 more sources

Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes

Clinical Pharmacology & Therapeutics, 2023
Genetic polymorphisms in drug metabolizing enzymes and drug–drug interactions are major sources of inadequate drug exposure and ensuing adverse effects or insufficient responses. The current challenge in assessing drug–drug gene interactions (DDGIs) for the development of precise dose adjustment recommendation systems is to take ...
Roberto Viviani, Judith Berres, Julia C. Stingl   +2 more
openaire   +4 more sources

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug-Drug-Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals. [PDF]

Clin Pharmacokinet, 2020
Metformin is a widely prescribed antidiabetic BCS Class III drug (low permeability) that depends on active transport for its absorption and disposition. It is recommended by the US Food and Drug Administration as a clinical substrate of organic cation transporter 2/multidrug and toxin extrusion protein for drug-drug interaction studies. Cimetidine is a
Hanke N, Türk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, Müller F, Stopfer P, Nock V, Lehr T.   +9 more
europepmc   +4 more sources

Drug–drug–gene interactions and adverse drug reactions [PDF]

The Pharmacogenomics Journal, 2019
AbstractThe economic and health burden caused by adverse drug reactions has increased dramatically in the last few years. This is likely to be mediated by increasing polypharmacy, which increases the likelihood for drug–drug interactions. Tools utilized by healthcare practitioners to flag potential adverse drug reactions secondary to drug–drug ...
Malki, Mustafa Adnan, Pearson, Ewan Robert   +1 more
openaire   +3 more sources

A Review of Current In Silico Methods for Repositioning Drugs and Chemical Compounds

Frontiers in Oncology, 2021
Drug repositioning is a new way of applying the existing therapeutics to new disease indications. Due to the exorbitant cost and high failure rate in developing new drugs, the continued use of existing drugs for treatment, especially anti-tumor drugs ...
Binsheng He, Fangxing Hou, Changjing Ren, Changjing Ren, Pingping Bing, Xiangzuo Xiao   +5 more
doaj   +1 more source

Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition

Computational and Structural Biotechnology Journal, 2020
In recent decades the identification of pharmacogenomic gene-drug associations has evolved tremendously. Despite this progress, a major fraction of the heritable inter-individual variability remains elusive.
Yitian Zhou, Volker M. Lauschke
doaj   +1 more source